Status | In progress |
Process | STA 2018 |
ID number | 1304 |
Provisional Schedule
Committee meeting: 1 | 12 March 2020 |
Expected publication | 27 May 2020 |
Project Team
Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email TACommE@nice.org.uk
Evidence Review Group / Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
Companies sponsors | Novartis (siponimod) |
Others | Department of Health and Social Care |
NHS England | |
Welsh Government | |
Patient carer groups | Multiple Sclerosis Society |
Multiple Sclerosis Trust | |
Professional groups | Association of British Neurologists |
Royal College of Physicians | |
UK Clinical Pharmacy Association | |
UK Multiple Sclerosis Specialist Nurse Association |
Commentators
Comparator companies | Novartis (interferon beta 1b) |
Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating) | |
Biogen (dimethyl fumarate, interferon beta 1a) | |
Merck (interferon beta 1a) (confidentiality agreement not signed, not participating) | |
Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating) | |
Roche (ocrelizumab) | |
Sanofi Genzyme (teriflunomide) | |
Teva (glatiramer acetate(confidentiality agreement not signed, not participating) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
16 July 2019 | Invitation to participate |
16 July 2019 | In progress, Appraisal has been referred to NICE. |
20 November 2018 - 18 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance